These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 10620018)

  • 1. Region between alpha-helices 3 and 4 of the mad homology 2 domain of Smad4: functional roles in oligomer formation and transcriptional activation.
    Tada K; Inoue H; Ebisawa T; Makuuchi M; Kawabata M; Imamura T; Miyazono K
    Genes Cells; 1999 Dec; 4(12):731-41. PubMed ID: 10620018
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The transforming growth factor-beta/SMAD signaling pathway is present and functional in human mesangial cells.
    Poncelet AC; de Caestecker MP; Schnaper HW
    Kidney Int; 1999 Oct; 56(4):1354-65. PubMed ID: 10504488
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The transcriptional co-activator P/CAF potentiates TGF-beta/Smad signaling.
    Itoh S; Ericsson J; Nishikawa J; Heldin CH; ten Dijke P
    Nucleic Acids Res; 2000 Nov; 28(21):4291-8. PubMed ID: 11058129
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Smad proteins exist as monomers in vivo and undergo homo- and hetero-oligomerization upon activation by serine/threonine kinase receptors.
    Kawabata M; Inoue H; Hanyu A; Imamura T; Miyazono K
    EMBO J; 1998 Jul; 17(14):4056-65. PubMed ID: 9670020
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential ubiquitination defines the functional status of the tumor suppressor Smad4.
    Morén A; Hellman U; Inada Y; Imamura T; Heldin CH; Moustakas A
    J Biol Chem; 2003 Aug; 278(35):33571-82. PubMed ID: 12794086
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Smad4 activation domain (SAD) is a proline-rich, p300-dependent transcriptional activation domain.
    de Caestecker MP; Yahata T; Wang D; Parks WT; Huang S; Hill CS; Shioda T; Roberts AB; Lechleider RJ
    J Biol Chem; 2000 Jan; 275(3):2115-22. PubMed ID: 10636916
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor-derived C-terminal mutations of Smad4 with decreased DNA binding activity and enhanced intramolecular interaction.
    Kuang C; Chen Y
    Oncogene; 2004 Feb; 23(5):1021-9. PubMed ID: 14647410
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An extended bipartite nuclear localization signal in Smad4 is required for its nuclear import and transcriptional activity.
    Xiao Z; Latek R; Lodish HF
    Oncogene; 2003 Feb; 22(7):1057-69. PubMed ID: 12592392
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Smads in human trophoblast cells: expression, regulation and role in TGF-beta-induced transcriptional activity.
    Wu D; Luo S; Wang Y; Zhuang L; Chen Y; Peng C
    Mol Cell Endocrinol; 2001 Apr; 175(1-2):111-21. PubMed ID: 11325521
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dual role of the Smad4/DPC4 tumor suppressor in TGFbeta-inducible transcriptional complexes.
    Liu F; Pouponnot C; Massagué J
    Genes Dev; 1997 Dec; 11(23):3157-67. PubMed ID: 9389648
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of p300, a transcriptional coactivator, in signalling of TGF-beta.
    Nishihara A; Hanai JI; Okamoto N; Yanagisawa J; Kato S; Miyazono K; Kawabata M
    Genes Cells; 1998 Sep; 3(9):613-23. PubMed ID: 9813111
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TGF-beta receptor-mediated signalling through Smad2, Smad3 and Smad4.
    Nakao A; Imamura T; Souchelnytskyi S; Kawabata M; Ishisaki A; Oeda E; Tamaki K; Hanai J; Heldin CH; Miyazono K; ten Dijke P
    EMBO J; 1997 Sep; 16(17):5353-62. PubMed ID: 9311995
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanism of a transcriptional cross talk between transforming growth factor-beta-regulated Smad3 and Smad4 proteins and orphan nuclear receptor hepatocyte nuclear factor-4.
    Chou WC; Prokova V; Shiraishi K; Valcourt U; Moustakas A; Hadzopoulou-Cladaras M; Zannis VI; Kardassis D
    Mol Biol Cell; 2003 Mar; 14(3):1279-94. PubMed ID: 12631740
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alternatively spliced variant of Smad2 lacking exon 3. Comparison with wild-type Smad2 and Smad3.
    Yagi K; Goto D; Hamamoto T; Takenoshita S; Kato M; Miyazono K
    J Biol Chem; 1999 Jan; 274(2):703-9. PubMed ID: 9873005
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TGF-beta-induced nuclear localization of Smad2 and Smad3 in Smad4 null cancer cell lines.
    Fink SP; Mikkola D; Willson JK; Markowitz S
    Oncogene; 2003 Mar; 22(9):1317-23. PubMed ID: 12618756
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of a bone morphogenetic protein-responsive Smad-binding element.
    Kusanagi K; Inoue H; Ishidou Y; Mishima HK; Kawabata M; Miyazono K
    Mol Biol Cell; 2000 Feb; 11(2):555-65. PubMed ID: 10679014
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutations in the tumor suppressors Smad2 and Smad4 inactivate transforming growth factor beta signaling by targeting Smads to the ubiquitin-proteasome pathway.
    Xu J; Attisano L
    Proc Natl Acad Sci U S A; 2000 Apr; 97(9):4820-5. PubMed ID: 10781087
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification and characterization of constitutively active Smad2 mutants: evaluation of formation of Smad complex and subcellular distribution.
    Funaba M; Mathews LS
    Mol Endocrinol; 2000 Oct; 14(10):1583-91. PubMed ID: 11043574
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alpha-helix 2 in the amino-terminal mad homology 1 domain is responsible for specific DNA binding of Smad3.
    Kusanagi K; Kawabata M; Mishima HK; Miyazono K
    J Biol Chem; 2001 Jul; 276(30):28155-63. PubMed ID: 11382774
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Roles of mono-ubiquitinated Smad4 in the formation of Smad transcriptional complexes.
    Wang B; Suzuki H; Kato M
    Biochem Biophys Res Commun; 2008 Nov; 376(2):288-92. PubMed ID: 18783722
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.